Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This kinase inhibitor is an experimental therapeutic program being developed by Hope Medicine specifically for the treatment or prevention of chemotherapy-induced toxicity. As of the current pipeline disclosures, the specific molecular kinase target has not been identified, and the drug is referred to by its functional class. The program aims to mitigate the adverse side effects associated with cytotoxic chemotherapy, potentially improving patient tolerance and treatment outcomes. It is currently in the early stages of development (Exploratory to Phase I/II range) within the company's internal pipeline.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hope Medicine kinase inhibitor (chemotherapy toxicity).